ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-12 07:30:00,2024-04-12T07:30:00-04:00,2024-04-12,AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine,"-     Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine -     Seventy percent of subjects achieved ≥50% reduction in monthly migraine days at Weeks 13-16 and this was consistent during the 48 weeks of open-label treatment -      Findings will be showcased in an oral presentation at the American Academy of Neurology (AAN) Annual Meeting Scientific Platform Session for Emerging Science NORTH CHICAGO, Ill. , April 12, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-announces-late-breaking-data-at-aan-supporting-long-term-safety-and-efficacy-of-atogepant-qulipta-for-preventive-treatment-of-migraine-302114992.html,https://images.financialmodelingprep.com/news/abbvie-announces-latebreaking-data-at-aan-supporting-longterm-safety-20240412.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-12 11:35:55,2024-04-12T11:35:55-04:00,2024-04-12,"AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%","AbbVie's stock has outperformed the market over the past decade, with a 248.90% appreciation. Despite losing patent protection for Humira, which accounted for 37% of revenue in 2022, AbbVie remains undervalued and continues to grow its dividend. AbbVie's recent acquisitions and robust pipeline position the company for future growth and expansion.",seekingalpha.com,https://seekingalpha.com/article/4683477-abbvie-despite-the-run-shares-still-look-attractive-yielding-3-67-percent,https://images.financialmodelingprep.com/news/abbvie-despite-the-run-shares-still-look-attractive-yielding-20240412.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-12 13:53:00,2024-04-12T13:53:00-04:00,2024-04-12,INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors,"BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) investors concerning the Company's possible violations of federal securities laws. On April 4, 2024, AbbVie disclosed that its prior financial guidance excluded the impact of acquired In-Process Research and Development (“IPR&D”) and milestone expense. The Company also disclosed that its earnings for the first quarter of 2024 “are expect.",businesswire.com,https://www.businesswire.com/news/home/20240412578742/en/INVESTOR-ALERT-Law-Offices-of-Howard-G.-Smith-Announces-Investigation-of-AbbVie-Inc.-ABBV-on-Behalf-of-Investors/,https://images.financialmodelingprep.com/news/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-abbvie-20240412.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-12 14:10:54,2024-04-12T14:10:54-04:00,2024-04-12,AbbVie: Bulletproof Fundamentals,"AbbVie is a profitability superstar with a strong track record of success, generating almost 40% in free cash flow margin. The company has a diverse portfolio of products across several promising drug markets, including an intact position in the immunology drugs market. The stock offers an attractive valuation, a solid dividend yield, and is recommended as a ""Strong Buy"" for long-term investors.",seekingalpha.com,https://seekingalpha.com/article/4683506-abbvie-bulletproof-fundamentals,https://images.financialmodelingprep.com/news/abbvie-bulletproof-fundamentals-20240412.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-12 16:00:00,2024-04-12T16:00:00-04:00,2024-04-12,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors","LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your AbbVie investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can.",businesswire.com,https://www.businesswire.com/news/home/20240412893900/en/Glancy-Prongay-Murray-LLP-a-Leading-Securities-Fraud-Law-Firm-Announces-Investigation-of-AbbVie-Inc.-ABBV-on-Behalf-of-Investors/,https://images.financialmodelingprep.com/news/glancy-prongay-murray-llp-a-leading-securities-fraud-law-firm-announces-investigation-of-20240412.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-14 01:23:00,2024-04-14T01:23:00-04:00,2024-04-14,Is AbbVie a Millionaire Maker?,AbbVie has a handful of desirable features as an investment. It's also navigating a period of uncertainty successfully so far.,fool.com,https://www.fool.com/investing/2024/04/14/is-abbvie-a-millionaire-maker/,https://images.financialmodelingprep.com/news/is-abbvie-a-millionaire-maker-20240414.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-15 08:36:51,2024-04-15T08:36:51-04:00,2024-04-15,"These four halal, Shariah-compliant stocks are best buys after Eid al-Fitr","If you want to invest in some new halal stocks, you know that finding companies compliant with Shariah law can be complicated.",invezz.com,https://invezz.com/news/2024/04/15/these-four-halal-shariah-compliant-stocks-are-best-buys-after-eid-al-fitr/,https://images.financialmodelingprep.com/news/these-four-halal-shariahcompliant-stocks-are-best-buys-after-20240415.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-16 10:05:24,2024-04-16T10:05:24-04:00,2024-04-16,AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",zacks.com,https://www.zacks.com/stock/news/2255886/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2255886,https://images.financialmodelingprep.com/news/abbvie-inc-abbv-is-attracting-investor-attention-here-is-20240416.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-16 11:45:00,2024-04-16T11:45:00-04:00,2024-04-16,Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies,"MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will use its commercial-stage long-acting injectable technology platform to formulate innovative therapies. Medincell will conduct formulation activities and preclinical studies, including supportive CMC work to advance candidates into clinical trials.",businesswire.com,https://www.businesswire.com/news/home/20240415916262/en/Medincell-Enters-Into-Strategic-Co-development-and-Licensing-Agreement-with-AbbVie-to-Develop-Next-generation-Long-acting-Injectable-Therapies/,https://images.financialmodelingprep.com/news/medincell-enters-into-strategic-codevelopment-and-licensing-agreement-with-abbvie-20240416.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-16 11:45:00,2024-04-16T11:45:00-04:00,2024-04-16,Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies,"MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will use its commercial-stage long-acting injectable technology platform to formulate innovative therapies. Medincell will conduct formulation activities and preclinical studies, including supportive CMC work to advance candidates into clinical trials. AbbVie will fina.",businesswire.com,https://www.businesswire.com/news/home/20240415101781/en/Medincell-Enters-Into-Strategic-Co-development-and-Licensing-Agreement-with-AbbVie-to-Develop-Next-generation-Long-acting-Injectable-Therapies/,https://images.financialmodelingprep.com/news/medincell-enters-into-strategic-codevelopment-and-licensing-agreement-with-20240416.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-16 14:56:16,2024-04-16T14:56:16-04:00,2024-04-16,"Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now","Blue-chip dividend stocks have always been relevant. While they're not the most exciting investments, they provide a steady hand during market uncertainty.",investorplace.com,https://investorplace.com/2024/04/steady-income-steady-growth-7-blue-chip-dividend-stocks-to-buy-now/,https://images.financialmodelingprep.com/news/steady-income-steady-growth-7-bluechip-dividend-stocks-to-20240416.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-17 09:35:07,2024-04-17T09:35:07-04:00,2024-04-17,Want $2000 In Passive Income? Invest $1000 Into These Dividend Stocks,"Naturally, one should monitor their portfolio on a regular basis in case there are any news events or market circumstances that can affect a stock price or its dividend adversely.",247wallst.com,https://247wallst.com/investing/2024/04/17/want-2000-in-passive-income-invest-1000-into-these-dividend-stocks/,https://images.financialmodelingprep.com/news/want-2000-in-passive-income-invest-1000-into-these-20240417.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-17 18:51:26,2024-04-17T18:51:26-04:00,2024-04-17,AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know,"AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.",zacks.com,https://www.zacks.com/stock/news/2257220/abbvie-abbv-increases-despite-market-slip-here-s-what-you-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2257220,https://images.financialmodelingprep.com/news/abbvie-abbv-increases-despite-market-slip-heres-what-you-20240417.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-18 08:31:00,2024-04-18T08:31:00-04:00,2024-04-18,Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis,"−     Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through week 52 compared to 29 percent of patients receiving placebo with a 52-week steroid taper regimen1 −     The safety profile in GCA was generally consistent with that in approved indications, and no new safety signals were identified1  −     The clinical program reflects AbbVie's history of developing new treatment options for patients with immune-mediated diseases, where there remains significant unmet medical need NORTH CHICAGO, Ill. , April 18, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA).",prnewswire.com,https://www.prnewswire.com/news-releases/phase-3-select-gca-study-of-upadacitinib-rinvoq-showed-positive-results-in-patients-with-giant-cell-arteritis-302120893.html,https://images.financialmodelingprep.com/news/phase-3-selectgca-study-of-upadacitinib-rinvoq-showed-positive-20240418.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-19 11:06:36,2024-04-19T11:06:36-04:00,2024-04-19,Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline,AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,zacks.com,https://www.zacks.com/stock/news/2258527/earnings-preview-abbvie-abbv-q1-earnings-expected-to-decline?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2258527,https://images.financialmodelingprep.com/news/earnings-preview-abbvie-abbv-q1-earnings-expected-to-decline-20240419.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-20 07:00:00,2024-04-20T07:00:00-04:00,2024-04-20,"20 Years To $300k? Building A $10,000 Dividend Portfolio From Scratch","Focusing on consistent dividend growth can lead to higher returns in lower-risk areas. The portfolio emphasizes companies with wide-moat business models, strong financials, and a commitment to shareholder returns. Blending higher-yielding dividend stocks with those offering growth potential creates a balanced approach suitable for most investors.",seekingalpha.com,https://seekingalpha.com/article/4684804-20-years-to-300k-building-a-10000-dividend-portfolio-from-scratch,https://images.financialmodelingprep.com/news/20-years-to-300k-building-a-10000-dividend-portfolio-20240420.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-23 10:21:24,2024-04-23T10:21:24-04:00,2024-04-23,Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics,Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.,zacks.com,https://www.zacks.com/stock/news/2259945/gear-up-for-abbvie-abbv-q1-earnings-wall-street-estimates-for-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2259945,https://images.financialmodelingprep.com/news/gear-up-for-abbvie-abbv-q1-earnings-wall-street-20240423.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-23 16:41:25,2024-04-23T16:41:25-04:00,2024-04-23,Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes,"Because dividend investing has such an impressive track record of beating non-dividend-paying stocks, many investors buy Dividend Aristocrats for their portfolios. It's not a bad strategy to begin with.",investorplace.com,https://investorplace.com/2024/04/dividend-growth-stars-7-stocks-with-10-year-double-digit-rate-hikes/,https://images.financialmodelingprep.com/news/dividend-growth-stars-7-stocks-with-10year-doubledigit-rate-20240423.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-24 10:21:05,2024-04-24T10:21:05-04:00,2024-04-24,What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?,"Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.",zacks.com,https://www.zacks.com/stock/news/2261011/what-s-in-store-for-these-5-pharma-bigwigs-in-q1-earnings?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview_-_esp-2261011,https://images.financialmodelingprep.com/news/whats-in-store-for-these-5-pharma-bigwigs-in-20240424.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-24 11:11:06,2024-04-24T11:11:06-04:00,2024-04-24,4 Large Drug Stocks to Hold on to Amid Industry Challenges,"Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.",zacks.com,https://www.zacks.com/commentary/2260758/4-large-drug-stocks-to-hold-on-to-amid-industry-challenges?cid=CS-STOCKNEWSAPI-FT-industry_outlook-2260758,https://images.financialmodelingprep.com/news/4-large-drug-stocks-to-hold-on-to-amid-industry-20240424.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-24 13:06:03,2024-04-24T13:06:03-04:00,2024-04-24,Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?,"While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.",zacks.com,https://www.zacks.com/stock/news/2261491/will-healthcare-etfs-lose-momentum-as-q1-earnings-unfold?cid=CS-STOCKNEWSAPI-FT-etf_news_and_commentary-2261491,https://images.financialmodelingprep.com/news/will-healthcare-etfs-lose-momentum-as-q1-earnings-unfold-20240424.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-25 08:00:00,2024-04-25T08:00:00-04:00,2024-04-25,New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study,"Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161 LEVEL UP, a Phase 3b/4 head-to-head study, compared upadacitinib to dupilumab for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis who had inadequate response to systemic therapy or when use of those therapies was inadvisable 1 The safety profile of upadacitinib was consistent with the profile in previous atopic dermatitis studies with no new safety signals identified during the 16-week period1,2 NORTH CHICAGO, Ill. , April 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib (RINVOQ®, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (DUPIXENT®, per its labeled dose) in adults and adolescents (≥12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable.",prnewswire.com,https://www.prnewswire.com/news-releases/new-data-show-rinvoq-upadacitinib-demonstrated-superiority-versus-dupixent-dupilumab-across-primary-and-all-secondary-endpoints-in-an-open-label-head-to-head-atopic-dermatitis-study-302126897.html,https://images.financialmodelingprep.com/news/new-data-show-rinvoq-upadacitinib-demonstrated-superiority-versus-dupixent-20240425.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-25 08:10:00,2024-04-25T08:10:00-04:00,2024-04-25,"March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys","Global stock indices continued an upward trend in March, with both U.S. and non-U.S. stocks rising by 3%.",seekingalpha.com,https://seekingalpha.com/article/4685904-marchs-dividend-portfolio-update-sets-new-all-time-record-100-holdings-21-buys,https://images.financialmodelingprep.com/news/marchs-dividend-portfolio-update-sets-new-alltime-record-100-20240425.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-25 08:48:05,2024-04-25T08:48:05-04:00,2024-04-25,AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study,"AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvies-skin-disease-drug-found-be-more-effective-than-regenerons-dupixent-study-2024-04-25/,https://images.financialmodelingprep.com/news/abbvies-skin-disease-drug-found-to-be-more-effective-20240425.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-26 07:35:00,2024-04-26T07:35:00-04:00,2024-04-26,AbbVie Reports First-Quarter 2024 Financial Results,"Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $12.310 Billion, an Increase of 0.7 Percent on a Reported Basis and 1.6 Percent on an Operational Basis First -Quarter Global Net Revenues from the Immunology Portfolio Were $5.371 Billion, a Decrease of 3.9 Percent on a Reported Basis, or 3.1 Percent on an Operational Basis, Due to Humira Biosimilar Competition; Global Humira Net Revenues Were $2.270 Billion; Global Skyrizi Net Revenues Were $2.008 Billion; Global Rinvoq Net Revenues Were $1.093 Billion First -Quarter Global Net Revenues from the Oncology Portfolio Were $1.543 Billion, an Increase of 9.0 Percent on a Reported Basis, or 9.8 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $838 Million; Global Venclexta Net Revenues Were $614 Million First -Quarter Global Net Revenues from the Neuroscience Portfolio Were $1.965 Billion, an Increase of 15.9 Percent on a Reported Basis, or 16.0 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $748 Million; Global Vraylar Net Revenues Were $694 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were $334 Million First -Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.249 Billion, a Decrease of 4.0 Percent on a Reported Basis, or 2.5 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $633 Million; Global Juvederm Net Revenues Were $297 Million Successfully Completed Acquisition of ImmunoGen and its Flagship Cancer Therapy, Elahere Raises 2024 Adjusted Diluted EPS Guidance Range from $10.97 - $11.17 to $11.13 - $11.33, which Includes an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and Milestones Expense Incurred During the First Quarter 2024 NORTH CHICAGO, Ill. , April 26, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2024.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-reports-first-quarter-2024-financial-results-302128164.html,https://images.financialmodelingprep.com/news/abbvie-reports-firstquarter-2024-financial-results-20240426.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-26 07:36:00,2024-04-26T07:36:00-04:00,2024-04-26,AbbVie's first-quarter results top expectations as arthritis drugs fuel growth,"AbbVie Inc. on Friday reported first-quarter results that beat expectations, even as sales of blockbuster autoimmune drug Humira continued to fall amid new, lower-cost competition.",marketwatch.com,https://www.marketwatch.com/story/abbvies-first-quarter-results-top-expectations-as-arthritis-drugs-fuel-growth-f4fd7fe3,https://images.financialmodelingprep.com/news/abbvies-firstquarter-results-top-expectations-as-arthritis-drugs-fuel-20240426.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-26 07:44:42,2024-04-26T07:44:42-04:00,2024-04-26,AbbVie lifts profit forecast after Skyrizi sales beat expectations,AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-annual-profit-forecast-strong-skyrizi-sales-2024-04-26/,https://images.financialmodelingprep.com/news/abbvie-lifts-profit-forecast-after-skyrizi-sales-beat-expectations-20240426.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-26 08:04:00,2024-04-26T08:04:00-04:00,2024-04-26,AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Fall,AbbVie reports better-than-expected adjusted earnings in the first quarter.,barrons.com,https://www.barrons.com/articles/abbvie-earnings-stock-price-cd6c5343,https://images.financialmodelingprep.com/news/abbvie-raises-earnings-guidance-even-as-humira-sales-continue-20240426.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-26 08:17:26,2024-04-26T08:17:26-04:00,2024-04-26,AbbVie's Q1 earnings beat expectations as arthritis drug boosts growth,"Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q1 financial results for 2024 today. AbbVie's earnings came in at $1.37 billion, or $0.77 per share, as compared with $239 million, or $0.13 per share, in Q1 of FY23.",invezz.com,https://invezz.com/news/2024/04/26/abbvies-q1-earnings-beat-expectations-as-arthritis-drug-boosts-growth/,https://images.financialmodelingprep.com/news/abbvies-q1-earnings-beat-expectations-as-arthritis-drug-boosts-20240426.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-26 08:17:26,2024-04-26T08:17:26-04:00,2024-04-26,AbbVie's Q1 earnings beat expectations as arthritis drug boosts growth,"Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q1 financial results for 2024 today. AbbVie's earnings came in at $1.37 billion, or $0.77 per share, as compared with $239 million, or $0.13 per share, in Q1 of FY23.",invezz.com,https://invezz.com/news/2024/04/26/abbvies-q1-earnings-beat-expectations-as-arthritis-drug-boosts-growth/?utm_source=snapi,https://images.financialmodelingprep.com/news/abbvies-q1-earnings-beat-expectations-as-arthritis-drug-boosts-growth-20240426.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-26 09:03:32,2024-04-26T09:03:32-04:00,2024-04-26,AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title,"AbbVie stock was muted Friday after beating first-quarter expectations as Humira sales continue falling. Skyrizi is catching up, though.",investors.com,https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q1-2024/,https://images.financialmodelingprep.com/news/abbvie-beats-firstquarter-views-as-skyrizi-looks-to-take-20240426.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-26 09:46:23,2024-04-26T09:46:23-04:00,2024-04-26,AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates,"AbbVie (ABBV) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.46 per share a year ago.",zacks.com,https://www.zacks.com/stock/news/2263059/abbvie-abbv-beats-q1-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2263059,https://images.financialmodelingprep.com/news/abbvie-abbv-beats-q1-earnings-and-revenue-estimates-20240426.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-26 11:30:27,2024-04-26T11:30:27-04:00,2024-04-26,AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say,"While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",zacks.com,https://www.zacks.com/stock/news/2263404/abbvie-abbv-reports-q1-earnings-what-key-metrics-have-to-say?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2263404,https://images.financialmodelingprep.com/news/abbvie-abbv-reports-q1-earnings-what-key-metrics-have-20240426.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-26 13:11:15,2024-04-26T13:11:15-04:00,2024-04-26,"AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View",AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.,zacks.com,https://www.zacks.com/stock/news/2263588/abbvie-abbv-beats-on-q1-earnings-sales-ups-24-eps-view?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2263588,https://images.financialmodelingprep.com/news/abbvie-abbv-beats-on-q1-earnings-sales-ups-24-20240426.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-26 15:25:40,2024-04-26T15:25:40-04:00,2024-04-26,AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump,"Shares of AbbVie (ABBV) slumped Friday as the pharmaceutical firm warned of deeper declines in sales of its blockbuster arthritis drug, Humira, because of competition from close copies known as biosimilars.",investopedia.com,https://www.investopedia.com/abbvie-stock-falls-as-company-warns-of-continued-humira-sales-slump-8639749,https://images.financialmodelingprep.com/news/abbvie-stock-falls-as-company-warns-of-continued-humira-20240426.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-26 16:07:11,2024-04-26T16:07:11-04:00,2024-04-26,Why AbbVie Stock Stumbled Today Despite the Earnings Beat,"Drugmaker AbbVie topped sales and earnings expectations in Q1, although those expectations were modest. The leading products in its portfolio are changing quickly, which makes it difficult to determine what the future holds.",fool.com,https://www.fool.com/investing/2024/04/26/why-abbvie-stock-stumbled-today-despite-the-earnin/,https://images.financialmodelingprep.com/news/why-abbvie-stock-stumbled-today-despite-the-earnings-beat-20240426.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-27 07:15:00,2024-04-27T07:15:00-04:00,2024-04-27,3 Dividend Stocks to Buy and Hold for the Next Decade,AbbVie is an unstoppable passive income machine. Eli Lilly offers a sizzling stock performance and a growing dividend.,fool.com,https://www.fool.com/investing/2024/04/27/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/,https://images.financialmodelingprep.com/news/3-dividend-stocks-to-buy-and-hold-for-the-20240427.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-28 04:20:00,2024-04-28T04:20:00-04:00,2024-04-28,Better Dividend Stock: AbbVie or Johnson & Johnson?,"AbbVie and Johnson & Johnson have excellent dividend track records and solid businesses. However, one of these healthcare giants has a slight edge over the other.",fool.com,https://www.fool.com/investing/2024/04/28/better-dividend-stock-abbvie-or-johnson-johnson/,https://images.financialmodelingprep.com/news/better-dividend-stock-abbvie-or-johnson-johnson-20240428.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-30 06:32:00,2024-04-30T06:32:00-04:00,2024-04-30,Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing,Investors rarely have a reason to ignore Dividend Aristocrat stocks. That's doubly true today with inflation remaining stubbornly high.,investorplace.com,https://investorplace.com/2024/04/inflation-proof-fortunes-7-dividend-aristocrats-to-keep-your-wealth-growing/,https://images.financialmodelingprep.com/news/inflationproof-fortunes-7-dividend-aristocrats-to-keep-your-wealth-20240430.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-30 09:11:35,2024-04-30T09:11:35-04:00,2024-04-30,"Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher","AbbVie Inc. NYSE: ABBV stock is recovering after falling over 4% in the week preceding its earnings report on April 26, 2024. As the market closed on Monday, April 29, ABBV stock posted a gain of 1.19% that could signal a floor is in after a recent sell-off in the biopharmaceutical company's stock.",marketbeat.com,https://www.marketbeat.com/stock-ideas/analyst-sentiment-revenue-growth-will-lead-abbvie-stock-higher/,https://images.financialmodelingprep.com/news/analyst-sentiment-revenue-growth-will-lead-abbvie-stock-higher-20240430.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-30 09:59:20,2024-04-30T09:59:20-04:00,2024-04-30,2 Dividend Stocks To Watch In May 2024,Dividend stocks for your May 2024 watch list.,stockmarket.com,https://stockmarket.com/featured/2-dividend-stocks-to-watch-in-may-2024-2024-04-30,https://images.financialmodelingprep.com/news/2-dividend-stocks-to-watch-in-may-2024-20240430.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-30 12:46:04,2024-04-30T12:46:04-04:00,2024-04-30,AbbVie (ABBV) Could Be a Great Choice,"Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?",zacks.com,https://www.zacks.com/stock/news/2265269/abbvie-abbv-could-be-a-great-choice?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_5-2265269,https://images.financialmodelingprep.com/news/abbvie-abbv-could-be-a-great-choice-20240430.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-30 13:30:00,2024-04-30T13:30:00-04:00,2024-04-30,"FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'","WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.",marketwatch.com,https://www.marketwatch.com/story/ftc-challenges-bogus-patents-on-ozempic-other-drugs-that-block-competition-42cba52f,https://images.financialmodelingprep.com/news/ftc-challenges-bogus-patents-on-ozempic-other-drugs-that-20240430.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-04-30 13:50:57,2024-04-30T13:50:57-04:00,2024-04-30,7 Safe Haven Stocks That Can Withstand the Market's Worst Meltdowns,Everyone needs solace in stability and development in the current turbulent market climate. These are seven unwavering businesses that are well-known for their fundamental capability to withstand market downturns.,investorplace.com,https://investorplace.com/2024/04/7-safe-haven-stocks-that-can-withstand-the-markets-worst-meltdowns/,https://images.financialmodelingprep.com/news/7-safe-haven-stocks-that-can-withstand-the-markets-20240430.png
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-05-01 08:40:27,2024-05-01T08:40:27-04:00,2024-05-01,"Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors","AbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group's CEO will testify on Capitol Hill.",cnbc.com,https://www.cnbc.com/2024/05/01/healthy-returns-humira-sales-are-falling-but-abbvie-has-successors.html,https://images.financialmodelingprep.com/news/healthy-returns-sales-of-humira-are-plunging-but-abbvie-20240501.jpeg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-05-01 08:43:27,2024-05-01T08:43:27-04:00,2024-05-01,5 Dividend King Blue-Chips That Lagged the Market Are Incredible May Buys,∴ Sponsored: Want to Retire Early?,247wallst.com,https://247wallst.com/investing/2024/05/01/5-dividend-kings-blue-chips-that-lagged-the-market-are-incredible-may-buys/,https://images.financialmodelingprep.com/news/5-dividend-king-bluechips-that-lagged-the-market-are-20240501.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-05-01 10:06:14,2024-05-01T10:06:14-04:00,2024-05-01,Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock,"AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",zacks.com,https://www.zacks.com/stock/news/2265766/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2265766,https://images.financialmodelingprep.com/news/here-is-what-to-know-beyond-why-abbvie-inc-abbv-20240501.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-05-05 13:44:00,2024-05-05T13:44:00-04:00,2024-05-05,3 Reasons to Buy AbbVie Stock on the Dip,AbbVie's revenue grew slightly in the first quarter despite Humira losing steam. The company's successors to Humira are proving worthy.,fool.com,https://www.fool.com/investing/2024/05/05/3-reasons-to-buy-abbvie-stock-on-the-dip/,https://images.financialmodelingprep.com/news/3-reasons-to-buy-abbvie-stock-on-the-dip-20240505.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-05-06 08:00:00,2024-05-06T08:00:00-04:00,2024-05-06,AbbVie to Present at the Bank of America Securities Healthcare Conference,"NORTH CHICAGO, Ill. , May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-bank-of-america-securities-healthcare-conference-302133591.html,https://images.financialmodelingprep.com/news/abbvie-to-present-at-the-bank-of-america-securities-20240506.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-05-07 11:46:19,2024-05-07T11:46:19-04:00,2024-05-07,AbbVie Tracking for New Highs in 2024,"Shares of AbbVie NYSE: ABBV fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira portfolio, resilient business, and a solid pipeline.",marketbeat.com,https://www.marketbeat.com/stock-ideas/abbvie-tracking-for-new-highs-in-2024/,https://images.financialmodelingprep.com/news/abbvie-tracking-for-new-highs-in-2024-20240507.jpg
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-05-07 14:04:24,2024-05-07T14:04:24-04:00,2024-05-07,Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare,"Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.",investorplace.com,https://investorplace.com/2024/05/biotech-breakthroughs-7-stocks-driving-the-next-wave-in-healthcare/,https://images.financialmodelingprep.com/news/biotech-breakthroughs-7-stocks-driving-the-next-wave-in-20240507.png
ABBV,2024-04-26,2024-04-12,2024-05-10,ABBV,,2024-05-10 09:30:00,2024-05-10T09:30:00-04:00,2024-05-10,3 Rock-Solid Dividend Stocks That Are Ideal for Retirees,AbbVie is a diversified healthcare company that has been able to strengthen its portfolio via acquisitions. AT&T has faced a lot of negative press in recent years but its fundamentals remain sound.,fool.com,https://www.fool.com/investing/2024/05/10/3-rock-solid-dividend-stocks-ideal-for-retirees/,https://images.financialmodelingprep.com/news/3-rocksolid-dividend-stocks-that-are-ideal-for-retirees-20240510.jpg
